2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-180143
    VU6052254 3035701-02-8
    VU6052254, a derivative of VU0467319 (HY-173396), is a selective, potent, orally active and brain-penetrant muscarinic M1 acetylcholine receptor (mAChR1) positive allosteric modulator with an EC50 of 59 nM. VU6052254 has no activity on the M2-5 receptor (EC50 > 30 μM). VU6052254 can improve memory recognition ability and reverse the cognitive impairment induced by Scopolamine (HY-N0296) with minimum effective dose both of 1 mg/kg. VU6052254 can be used for the research of neurological disease, such as Alzheimer's disease.
    VU6052254
  • HY-180146
    BChE-IN-48
    BChE-IN-48 (Compound 12a) is a BChE inhibitor that can cross the blood-brain barrier with IC50 values for eqBChE and huBChE of 1.3 and 0.95 μM respectively. BChE-IN-48 exhibits an IC50 value for eeAChE of 8.6 μM. BChE-IN-48 exhibits significant neuroprotective activity in cell damage and significantly improves cognitive impairment in mouse models. BChE-IN-48 can be used for research on Alzheimer's disease.
    BChE-IN-48
  • HY-180155
    Keap1/Nrf2/ARE activator 2 3105470-83-2
    Keap1/Nrf2/ARE activator 2 is an activator of Keap1/Nrf2/ARE pathway and non-competitively inhibits AChE with an IC50 of 14.79 μM and a Ki of 1.35 μM. Keap1/Nrf2/ARE activator 2 promotes Nrf2 nuclear translocation, leading to antioxidant gene upregulation and enhanced cellular defense against oxidative stress. Keap1/Nrf2/ARE activator exhibits robust neuroprotection against both H2O2- and Scopolamine (SCA) (HY-N0296)-induced injury in PC12 cells. Keap1/Nrf2/ARE activator 2 ameliorates memory impairment and the neuro-inflammation associated with SCA-initiated cognitive dysfunction in a zebrafish model. Keap1/Nrf2/ARE activator 2 can be used for the research of Alzheimer's disease.
    Keap1/Nrf2/ARE activator 2
  • HY-180160
    Aβ aggregation-IN-3
    Aβ aggregation-IN-3 (Compound B7) is an Aβ aggregation inhibitor. Aβ aggregation-IN-3 inhibits Aβ aggregation. Aβ aggregation-IN-3 confers protection in both neuronal and microglial models. Aβ aggregation-IN-3 reduces Aβ-induced paralysis in C. elegans. Aβ aggregation-IN-3 improves Alzheimer's disease.
    Aβ aggregation-IN-3
  • HY-180185
    5-HT2A&5-HT2C agonist-2 98%
    5-HT2A&5-HT2C agonist-2 (Compound 3ci) is a highly selective dual 5-HT2A/5-HT2C agonist that can cross the blood-brain barrier and has an EC50 < 1 μM. 5-HT2A&5-HT2C agonist-2 has high selectivity for 5-HT2B related to the risk of heart valve disease. 5-HT2A&5-HT2C agonist-2 can induce head convulsive responses, but has a relatively low hallucinogenic potential. 5-HT2A&5-HT2C agonist-2 can be used in the research of diseases such as depression and obesity.
    5-HT2A&5-HT2C agonist-2
  • HY-180189
    Carbonic anhydrase-IN-37
    Carbonic anhydrase-IN-37 (compound 9a) is a potent and orally active carbonic anhydrase (CA) inhibitor with Kis of 9.7 and 1.0 nM for hCA VA and hCA VB, respectively. Carbonic anhydrase-IN-37 shows anti allodynic and antihyperalgesic effects on Paclitaxel (HY-B0015)-induced neuropathic pain in mice. Carbonic anhydrase-IN-37 can be used for neuropathic pain research.
    Carbonic anhydrase-IN-37
  • HY-180195
    Grp94-IN-3 98%
    Grp94-IN-3 (Compound 47) is a selective ATP competitive inhibitor of Grp94, with a Kd value of 76 nM. Grp94-IN-3 has a much lower affinity for Hsp90α, with a Kd value of 9.17 μM. Grp94-IN-3 induces the degradation of integrin α2 (Integrin α2) in MDA-MB-231 cells and reduces the intracellular accumulation of mutant cardiac proteins in human trabecular meshwork cells. Grp94-IN-3 can be used for the study of metastatic cancer and open-angle glaucoma.
    Grp94-IN-3
  • HY-180197
    PICK1 PDZ-IN-1
    PICK1 PDZ-IN-1 (Compound 6b) is a selective and brain-penetrant protein interacting with C kinase 1 (PICK1) PDZ domain inhibitor with a Ki of 27.73 μM. PICK1 PDZ-IN-1 can competitively inhibit the interaction between PICK1 and the GluA2 subunit of AMPA receptors. PICK1 PDZ-IN-1 can increase the survival rate of HT22 cells and primary cortical neuron cells induced by glutamate and inhibit ROS production. PICK1 PDZ-IN-1 exhibits neuroprotective effect and reduces the area of cerebral infarction. PICK1 PDZ-IN-1 can be used for the research of ischemic stroke.
    PICK1 PDZ-IN-1
  • HY-180212
    SYK-1106 2643940-93-4 98%
    SYK-1106 is a potent delta-opioid receptor (DOR) agonist with an EC50 of 89 pM and a Ki of 848 pM. SYK-1106 is selective for μ and κ opioid receptors, with Ki values of 9.54 nM and 2.45 nM, respectively. SYK-1106 induces dose-dependent antidepressant-like effects. SYK-1106 can be used for the research of depression.
    SYK-1106
  • HY-180214
    HDAC6-IN-69 98%
    HDAC6-IN-69 is a brain-penetrant and highly selective HDAC6 inhibitor with an IC50 of 4.0 nM. HDAC6-IN-69 shows >176-fold against other HDAC isoforms. HDAC6-IN-69 engages the target in neuronal cells by dose-dependently upregulating acetylated α-tubulin in virto. HDAC6-IN-69 has neuroprotective effect and can be used for ischemic stroke research .
    HDAC6-IN-69
  • HY-180225
    AChE-IN-101 98%
    AChE-IN-101 (Compound 7a) is an AChE inhibitor (IC50s = 0.21 μM (EeAChE); 13 nM (HsAChE)). AChE-IN-101 ameliorates Scopolamine (HY-N0296)-induced cognitive impairment. AChE-IN-101 can be used in the research of Alzheimer's disease.
    AChE-IN-101
  • HY-180243
    AChE-IN-102
    AChE-IN-102 (compound C8) is a potent, selective and competitive AChE inhibitor with a Ki of 7.55 nM and an IC50 of 15.25 nM. AChE-IN-102 shows selectivity over BuChE (IC50 = 21.15 nM, b>Ki = 6.17 nM). AChE-IN-102 can be used for Alzheimer’s disease research.
    AChE-IN-102
  • HY-180267
    (R)-Chloro-butylphthalide-O-NBP
    (R)-Chloro-butylphthalide-O-NBP, a chiral 3-n-butylphthalide derivative, is a neuroprotective agent. (R)-Chloro-butylphthalide-O-NBP shows potent blood-brain barrier (BBB) protective function. In vivo, (R)-Chloro-butylphthalide-O-NBP significantly reduces infarct volume and markedly preserves BBB integrity. (R)-Chloro-butylphthalide-O-NBP can be used for the research of ischemic stroke.
    (R)-Chloro-butylphthalide-O-NBP
  • HY-180296
    AChE-IN-103 113027-75-1
    AChE-IN-103 (Compound 10) is an inhibitor of ACh. AChE-IN-103 exhibits log IC50 values of 1.477 and 2.2 for models based on alignments I and II. AChE-IN-103 can be studied in research on Alzheimer’s disease.
    AChE-IN-103
  • HY-180320
    Lu AF58786 1632368-13-8 98%
    Lu AF58786 is a potent and selective LRRK2 inhibitor with an IC50 of 12 nM. Lu AF58786 also exhibits inhibition activity against LRRK2 G2019S and LRRK2 A2016T with IC50s of 19 and 93 nM. Lu AF58786 inhibits phosphorylation of LRRK2, Rab10 and Rab12 in human peripheral blood mononuclear cells. Lu AF58786 can be used for parkinson’s disease research.
    Lu AF58786
  • HY-180327
    NEPP11 313051-12-6
    NEPP11 is a cyclopentenone prostaglandin analogue. NEPP11 can inhibit glutamate-induced HT22 cell death in mouse hippocampus and prevent manganese-induced apoptosis in PC12 cells. NEPP11 can activate Nrf2 and maintain MEK1/2 and ERK1/2 activity by inhibiting c-Raf downregulation. NEPP11 exerts a neuroprotective effect in a mouse model of focal cerebral ischemia caused by permanent middle cerebral artery occlusion.
    NEPP11
  • HY-180338
    MLK-IN-3 105788-15-6
    MLK-IN-3 (Compound 30) is a MLK inhibitor with an IC50 of less than 5 μM. MLK-IN-3 can be used in the research of neurological diseases.
    MLK-IN-3
  • HY-180342
    Fenaperone hydrochloride 26964-71-6
    Fenaperone (hydrochloride) is a biochemical compound with neuroleptic activities.
    Fenaperone hydrochloride
  • HY-180345
    ND-7001 855170-53-5
    ND-7001 is an inhibitor of PDE2 with an IC50 of 0.05 μM. ND-7001 exhibits good selectivity agianst PDE3 and PDE4. ND-7001 increases cGMP levels in primary neuronal cultures of rat cerebral cortical neurons. ND-7001 displays anxiolytic effects.
    ND-7001
  • HY-180346
    Hepta-histidine 64134-31-2
    Hepta-histidine is an inhibitor of Ku70-Huntingtin protein interaction. Hepta-histidine can reverse the morphological abnormalities of primary neurons differentiatied from hiPSCs. Hepta-histidine prolongs the lifespan in severe Huntington’s disease R6/2 mouse model. Hepta-histidine ameliorates DNA damage in vitro. Hepta-histidine can be used to study anti-aggregation agent against Tau-associated neurodegenerative diseases such as Alzheimer’s disease and Huntington’s disease.
    Hepta-histidine
Cat. No. Product Name / Synonyms Application Reactivity